Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (403)	12/14/2008 1:02:29 PM
From: mcbio	Read Replies (1) \| Respond to of 566

Thanks George. The numbers for Enbrel are from a PDF on RIGL's Web site that shows efficacy numbers for other RA treatments. See "Literature Review of RA Treatments" at: rigel.com There's a lot of good information on RIGL's site. The other important matter aside from efficacy is of course safety. The three main concerns from R788 so far are hypertension, neutropenia, and a mild elevation in liver enzymes. I believe gastrointestinal concerns occurred at the twice daily dose of 150mg, which won't be used going forward. From what I have read, the aforementioned concerns were mostly alleviated when dose was reduced.